Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant
chemoradiation(CRT) in locally advanced rectal cancer. Half of participants will receive
capecitabine and along with neoadjuvant radiotherapy, followed by a cycle of XELIRI, while
the others will receive capecitabine and irinotecan added by amifostine during CRT, followed
by a cycle of XELIRI. All participants will be scheduled to receive surgery 6-8 weeks after
the completion of CRT. Then it will depends which regimens the patient would receive
according to his or her pathological results.